Boardroom Alpha
Meeting calendar
TRS · Annual meeting · Wednesday, May 20, 2026

Trimas Corp

9 nominees · 3 ballot items.

Elect two directors to serve until 2029; ratify Deloitte as independent auditor for 2026; approve, on a non-binding advisory basis, the compensation paid to the Company’s Named Executive Officers (Say-on-Pay).

Market cap
$1.5B
1Y TSR
+37.5%
Board grade
B-
Record date
Mar 23, 2026
Filing
DEF 14A
Meeting concluded · May 20, 2026

Follow how the vote landed and what changed on Trimas Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot3

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Elect two directors (Holly M. Boehne and Herbert K. Parker) to serve until the 2029 Annual Meeting.

  2. 2

    Ratification of Appointment of Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    Ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

  3. 3

    Approval, on a Non-Binding Advisory Basis, of the Compensation Paid to the Company’s Named Executive Officers

    ManagementBoard: FOR

    Non-binding advisory vote (Say-on-Pay) to approve the compensation paid to the Company’s Named Executive Officers as disclosed in the proxy statement.

    More detail

    This management proposal seeks a non-binding advisory approval (Say-on-Pay) of the compensation paid to the Company’s Named Executive Officers (NEOs) as presented in the proxy. Management is asking shareholders to affirm the overall executive compensation program, which is structured to align pay with performance via a mix of base salary, short-term incentives (STI), and long-term incentives (RSUs, PSUs and inducement awards), with significant pay-at-risk tied to performance metrics such as adjusted operating profit, cash flow, Cash RONA, EPS CAGR and RTSR. The Compensation Committee describes rigorous governance: use of an independent compensation consultant, stock ownership guidelines, clawback policy, prohibition on hedging/pledging, and an annual review of peer groups. The proposal is advisory and non-binding, but the Board indicates it will consider the vote outcome in future compensation decisions. Contextual factors include substantial management changes in 2025 (CEO and CFO transitions), one-time inducement awards to the CEO (premium-priced options and RSUs), and material corporate actions (the announced divestiture of TriMas Aerospace), all of which affected 2025 compensation decisions and may shape shareholder views. The Board recommends a “FOR” vote, arguing the program is market-aligned, performance-oriented, and designed to retain key executives during transition while aligning their interests with shareholders.

Director elections

Nominees on the ballot9

Independent
Tenure on this board
6.3 yrs
Also a director at
Union Pacific Corp (UNP)
Independent
Tenure on this board
11.4 yrs
Also a director at
Apogee Enterprises Inc (APOG)Nvent Electric PLC (NVT)Dauch Corp (DCH)
Independent
Tenure on this board
13.5 yrs
Also a director at
Hexcel Corp (HXL)Huntington Ingalls Industries Inc (HII)Ametek Inc (AME)
Ownership

Top institutional holders10

Latest 13F quarter
1BANK OF AMERICA CORP /DE/10.0%3,586,375$129M
2Allspring Global Investments Holdings, LLC7.0%2,508,555$91M
3DIMENSIONAL FUND ADVISORS LP6.0%2,148,045$77M
4VANGUARD PORTFOLIO MANAGEMENT LLC5.0%1,775,312$64M
5VANGUARD CAPITAL MANAGEMENT LLC4.4%1,581,339$57M
6Jefferies Financial Group Inc.4.3%1,549,662$56M
7MORGAN STANLEY3.8%1,363,293$49M
8Permian Investment Partners, LP3.4%1,202,500$43M
9BlackRock, Inc.3.2%1,135,217$41M
10ADVISORY RESEARCH INC3.0%1,089,251$39M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Trimas Corp 2026 annual meeting?
Trimas Corp (TRS) holds its 2026 annual shareholder meeting on Wednesday, May 20, 2026.
What is the record date for the Trimas Corp 2026 meeting?
The record date for the Trimas Corp 2026 meeting is Monday, March 23, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Trimas Corp's 2026 meeting?
The board is presenting 9 director nominees at the Trimas Corp 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Trimas Corp 2026 meeting?
Shareholders will vote on 3 proposals at the Trimas Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer